.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Farmers Insurance
Moodys
UBS
Federal Trade Commission
Fish and Richardson
Dow
US Army
McKinsey

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021877

« Back to Dashboard

NDA 021877 describes ARRANON, which is a drug marketed by Novartis Pharms Corp and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the ARRANON profile page.

The generic ingredient in ARRANON is nelarabine. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nelarabine profile page.

Summary for 021877

Tradename:1
Applicant:1
Ingredient:1
Patents:1

Pharmacology for NDA: 021877

Suppliers and Packaging for NDA: 021877

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ARRANON nelarabine INJECTABLE;IV (INFUSION) 021877 NDA GlaxoSmithKline LLC 0007-4401 0007-4401-06 6 VIAL, GLASS in 1 CARTON (0007-4401-06) > 50 mL in 1 VIAL, GLASS (0007-4401-01)
ARRANON nelarabine INJECTABLE;IV (INFUSION) 021877 NDA Novartis Pharmaceuticals Corporation 0078-0683 0078-0683-06 6 VIAL in 1 CARTON (0078-0683-06) > 50 mL in 1 VIAL (0078-0683-61)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;IV (INFUSION)Strength250MG/50ML (5MG/ML)
Approval Date:Oct 28, 2005TE:RLD:Yes
Patent:► SubscribePatent Expiration:Jun 13, 2017Product Flag?YSubstance Flag?YDelist Request?

Expired Orange Book Patents for NDA: 021877

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
Novartis Pharms CorpARRANONnelarabineINJECTABLE;IV (INFUSION)021877-001Oct 28, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Federal Trade Commission
UBS
Fuji
Chinese Patent Office
Teva
Colorcon
Dow
Argus Health
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot